The Longest Standing & Pre-Eminent European ADC Forum
16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers
Returning as the longest-standing and definitive ADC forum in Europe, 16th World ADC London 2026 is the must-attend event for anyone working in or looking to learn about bioconjugates. Leverage cutting-edge R&D, strategic insights, and unparalleled networking to advance ADC innovation and maximise therapeutic potential.
Agenda Highlights:
The 2026 programme features 5 end-to-end content streams covering discovery, preclinical translation, clinical lessons, process & analytical development, and manufacturing & supply chain. Sessions are infused with trailblazing approaches to overcome patient resistance and accelerate ADCs into earlier-line oncology treatments. Topics include:
- Novel cytotoxic and non-cytotoxic payloads
- Dual payload ADCs
- Bispecific and biparatopic ADCs
- Non-antibody and fragment conjugates
Global Speaker Faculty:
Hear from 110+ experts across Europe, North America, and Asia sharing actionable insights to advance your pipeline, including:
- Elaine Hurt, Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D, AstraZeneca
- Guillaume Bergthold, Executive Director, Clinical Development, Daiichi Sankyo
- Alan Russell, VP Research & Head, R&D Technology & Innovation, Amgen
- Andras Strassz, Chief Medical Officer, Heidelberg Pharma
- Marija Vrljic, VP, Antibody Technologies, ALX Oncology (New Company)
- Jonathan Davis, Director, ADC Discovery, Helix Biopharma (New Company)
- Zhenwei Miao, Founder & Chairman, Adcoris Biopharma (New Company)
Who Will Attend:
Join 800+ senior ADC decision-makers from biopharma, clinical research, service providers, investors, and regulators, uniting to shape the future of ADC development.
Explore the full agenda for a complete breakdown of all sessions, speakers, and networking opportunities.